-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Aardvark Therapeutics, Maintains $21 Price Target

Benzinga·04/01/2025 15:48:15
Listen to the news
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and maintains $21 price target.